The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Newsfile Corp

Canaccord Genuity Updates Buy Recommendation on TearLab Corporation - Video Posted on InvestmentPitch.com

Monday, May 27, 2013

Canaccord Genuity Updates Buy Recommendation on TearLab Corporation - Video Posted on InvestmentPitch.com

11:12 EDT Monday, May 27, 2013

Vancouver, British Columbia--(Newsfile Corp. - May 27, 2013) - Investment firm Canaccord Genuity has updated its buy recommendation on TearLab Corporation (NASDAQ: TEAR) (TSX: TLB). Analyst Jeffrey Frelick gives the company a buy rating and raised the one-year price target from US$10.00 to US$14.00, a 46% premium to the US$9.56 price the day the report was issued.

InvestmentPitch.com has produced a "video news alert" about TearLab based on this research report. If this link is not enabled, please visit www.InvestmentPitch.com and enter "TearLab" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_zqamqeyb/Canaccord-Genuity-updates-coverage-on-Tearlab-Corporation-NASDAQ-TEAR

TearLab has commercialized a proprietary tear testing platform, the TearLab Osmolarity System, that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point of care. Their first product measures tear film osmolarity for the diagnosis of dry eye disease.

Experts anticipate that dry Eye Syndrome will be the most prevalent eye disorder the Baby Boomer generation faces in the future.

Canaccord recently conducted interviews of TearLab users and found high levels of satisfaction from its customers.

As a result, analyst Jeffrey Frelick stated, "We gained comfort with our near-term assumptions and increased our instrument placements and utilization rates in 2015, resulting in raising our revenue expectations to $70 million from $65 million."

The shares are currently trading at US$10.00, and with 29 million shares outstanding, the company is capitalized at US$290 million. As stated earlier, this US$10.00 price is well below Canaccord Genuity's target price of US$14.00.

Canaccord cautions that investment risks would include lag time for CIJA waiver certificates, slow uptake by physicians, reimbursement risk, and other medical technology risks.

For more information, please visit the company's website www.TearLab.com or contact Stephen Kilmer at 647-872-4849 or email skilmer@tearlab.com .

For more information about Canaccord Genuity or to obtain a copy of their research report, contact your nearest Canaccord Genuity office. Their branches are listed on their website at www.canaccord.com .

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing three minute videos based on news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Customer Service
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections